（文章来源：第一财经） 在中国市场上，诺和诺德的司美格鲁肽糖尿病药物今年上半年的销售也出现11%左右的下滑。在财报公 布后的投资人电话会上，诺和诺德现任国际业务副总裁、即将于8月7日接替周赋德出任CEO的齐亚尔· 迈克·杜斯特达（Maziar Mike Doustdar）回应了投资人关于司美格鲁肽在中国市场上面临的竞争挑战。 杜斯特达表示，虽然中国GLP-1糖尿病药出现了下滑，但减重药销售是逐步增长的。他解释称，糖尿病 药销量出现下滑是由于经销商库存发生的变化；而去年刚刚获批的司美格鲁肽减重药目前还在放量阶 段，尚未进一步下沉到二、三、四线城市。 ...

司美格鲁肽第二季度总共实现79亿美元的收入，约占总收入的三分之二，销售额同比增长16%。不过， 在关键的美国市场上，司美格鲁肽糖尿病药物销量较前几年增速放缓。 8月6日，诺和诺德公布最新季度财报。财报显示该公司第二季度增长不及市场预期，在包括美国在内的 关键市场上，GLP-1类药物司美格鲁肽增速放缓。诺和诺德高管表示，将采取成本削减等举措。 财报显示，诺和诺德第二季度销售额增长18%至768.6亿丹麦克朗（约合119亿美元），较去年同期增长 18%，但低于分析师预期。此前因美国市场销售预期下降，诺和诺德已将2025年销售增长区间下调至 8%至14%。 第二季度，诺和诺德的GLP-1畅销药司美格鲁肽降糖和减重两种药物总共实现79亿美元的收入，约占总 收入的三分之二，销售额同比增长16%。不过，在关键的美国市场上，司美格鲁肽糖尿病药物销量较前 几年增速放缓，司美格鲁肽减重药市场份额也面临进一步下滑。 对此，即将于8月7日卸任的诺和诺德CEO周赋德（Lars Fruergaard Jørgensen）表示，尽管几年前公司拥 有市场的先发优势，但美国的司美格鲁肽复方仿制药流向市场，一直是诺和诺德在美国增长乏力的一个 ...

Group 1 - U.S. stock index futures are showing positive movement, with Dow futures up 0.29%, S&P 500 futures up 0.23%, and Nasdaq futures up 0.36% [1] - Chinese concept stocks are mixed in pre-market trading, with Alibaba up 1.53%, Pinduoduo up 1.07%, JD down 0.03%, Baidu up 0.87%, and Li Auto down 3.09% [2] - Uber's stock is down 0.17% in pre-market trading ahead of its Q2 earnings report scheduled for release [3] - AMD's stock is down over 5% in pre-market trading after reporting Q2 revenue that exceeded expectations but a significant drop in operating profit margin to 12% from 22% year-over-year, with adjusted net income down 31% to $781 million [4] - Advanced Micro Devices (AMD) reported a revenue increase but a decline in profitability, leading to a pre-market drop [4] Group 2 - Tesla is training a new Full Self-Driving (FSD) model, which is expected to have parameters ten times larger than the current version, with a potential public release by the end of next month [5] - Supermicro's stock is down over 16% in pre-market trading after significantly lowering its revenue guidance for the next quarter to between $6 billion and $7 billion, and reducing its fiscal 2026 revenue forecast by 17.5% to $33 billion [4] - Novo Nordisk reported a 67% year-over-year increase in sales for its weight loss drug Wegovy, reaching 19.53 billion Danish kroner in Q2 [6] - The U.S. Department of Health has withdrawn approximately $500 million in funding for mRNA vaccine development, affecting major vaccine manufacturers like Pfizer, Moderna, and Sanofi, with their stocks showing slight declines [7] - Disney has announced a significant deal involving ESPN and the NFL, exchanging equity and content rights to strengthen ties with a highly valuable sports IP, resulting in a 1.15% drop in Disney's stock [8]

Market Overview - The three major U.S. stock indices opened higher, with the Nasdaq up 0.18%, the S&P 500 up 0.14%, and the Dow Jones up 0.17% [1] Company Highlights - Apple shares rose by 1.7% after White House officials revealed that the company committed to investing an additional $100 billion in domestic manufacturing in the U.S. [1] - Nvidia's stock fell over 1% as the company issued a statement clarifying that its chips do not have backdoors, termination switches, or monitoring software [1] - Advanced Micro Devices (AMD) saw a decline of 6.6% as its adjusted net profit for the second quarter dropped 31% year-over-year, with data center business revenue growth falling short of expectations [1] - Super Micro Computer's stock plummeted by 17.6% after the company reported fourth-quarter results that missed expectations and significantly lowered its full-year revenue guidance [1] - Novo Nordisk's shares decreased by 3.2% as its second-quarter sales grew 18% year-over-year, which was below expectations, and the company anticipates a slowdown in GLP-1 drug growth in the second half of the year [1]

Core Viewpoint - Novo Nordisk's recent financial report indicates strong sales growth driven by its obesity care business, despite facing challenges in the U.S. market due to generic drug competition and slower market expansion [1][2][10]. Financial Performance - For the first half of 2025, Novo Nordisk reported sales of 154.9 billion Danish Krone (approximately 22.3 billion USD), a year-on-year increase of 18% at constant exchange rates [1]. - Operating profit reached 72.2 billion Krone (approximately 10.4 billion USD), reflecting a 29% year-on-year growth [1]. - The obesity care segment saw a remarkable sales increase of 56%, contributing significantly to overall growth [1]. Product Performance - The diabetes and obesity care division generated sales of 145.4 billion Krone (approximately 21.5 billion USD), with obesity drug sales rising 58% to 38.8 billion Krone (approximately 5.7 billion USD) [1]. - Specific product sales included Ozempic at 64.5 billion Krone (approximately 9.6 billion USD) with a 15% increase, Rybelsus at 11.3 billion Krone (approximately 1.7 billion USD) with a 5% increase, and Wegovy at 36.9 billion Krone (approximately 5.4 billion USD) with a 78% increase [1]. Market Challenges - In Q2 2025, operating profit was 33.4 billion Krone (approximately 4.8 billion USD), falling short of market expectations due to a slowdown in the U.S. market [2]. - The company has lowered its revenue and operating profit forecasts for 2025, citing decreased growth expectations for Wegovy and Ozempic in the U.S. market [10]. Industry Trends - The GLP-1 drug market is projected to exceed 17 billion USD by 2031, with a compound annual growth rate of 15.6% from 2021 to 2031 [5]. - There is a significant unmet need in obesity treatment, with only 27% of eligible patients currently receiving GLP-1 therapy in major markets [5]. Strategic Initiatives - Novo Nordisk is focusing on expanding its production capacity and adapting its product offerings to meet market demands [15][16]. - The company is investing in new facilities and partnerships to enhance its operational capabilities and direct patient outreach [11][16]. - The appointment of a new CEO aims to drive growth and navigate the competitive landscape in the metabolic disease treatment sector [14][17].

1. 8月6日(周三)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.35%，标普500指数期货涨0.24%，纳指期货涨 0.23%。 2. 截至发稿，德国DAX指数涨0.02%，英国富时100指数涨0.20%，法国CAC40指数涨0.28%，欧洲斯托克50指数涨0.22%。 3. 截至发稿，WTI原油涨1.63%，报66.22美元/桶。布伦特原油涨1.52%，报68.67美元/桶。 | 瑞 伦敦布伦特原油 | 2025年10月 | 68.67 | 68.81 | 67.65 | +1.03 | +1.52% | | --- | --- | --- | --- | --- | --- | --- | | 雪 WTI原油 | 2025年9月 | 66.22 | 66.34 | 65.12 | +1.06 | +1.63% | 市场消息 降息预期凌乱，华尔街投行"吵"起来。美国"非农"数据暴雷令美联储降息预期飙升，但本周华尔街知名投行对降息分歧却在加 大。高盛、花旗均认为，9月或激进降息，摩根大通甚至认为今年可能降息125个基点。然而，美银认为今年美联储或按兵不 动，巴克莱和汇丰同样态度谨慎。未来几个月将 ...

盘前市场动向 1. 8月6日(周三)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.35%，标普500指数期货涨0.24%，纳指期货涨 0.23%。 | = US 30 | 44,267.00 | 44,364.00 | 44,074.50 | +155.30 | +0.35% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,314.10 | 6,332.90 | 6,287.60 | +14.90 | +0.24% | | 트 US Tech 100 | 23,072.30 | 23,118.10 | 22,937.50 | +53.70 | +0.23% | 2. 截至发稿，德国DAX指数涨0.02%，英国富时100指数涨0.20%，法国CAC40指数涨0.28%，欧洲斯托克50指数涨0.22%。 | 德国DAX30 | 23,862.00 | 23,998.59 | 23,806.00 | +4.81 | +0.02% | | --- | --- | --- | --- | --- | --- | | 器 英国富时100 | 9,16 ...

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [8][42] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [42] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [46] Business Line Data and Key Metrics Changes - U.S. Operations sales grew by 17%, while international operations grew by 19% [12] - GLP-1 diabetes care sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - The company serves nearly 46 million patients with diabetes and obesity treatments, an increase of over 3.5 million patients compared to the first half of 2024 [10] - In international operations, GLP-1 diabetes sales increased by 10%, while obesity care sales grew by 125% [22] - The company holds a 71% market share in the GLP-1 segment in international operations [24] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [30] - A focus on innovation and operational efficiency is emphasized, with plans to enhance commercial execution [59] - The company is investing in a broad portfolio of treatments to address diverse patient segments in the obesity market [30] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [9][49] - The company remains confident in its ability to treat more patients with chronic diseases despite the adjustments in expectations [54] - The management highlighted the importance of addressing the unmet needs in diabetes and obesity globally [28] Other Important Information - The company has initiated a Phase III clinical development program for amicretin, targeting obesity and associated comorbidities [35] - The company plans to launch oral semaglutide for obesity in the U.S. next year without supply restrictions [103] - An interim dividend of DKK 3.75 per share has been announced, reflecting a 7% increase compared to the previous year [48] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the conversion from the CVS formulary and is seeing results in line with expectations [66] Question: Has Novo initiated any litigation regarding compounding practices? - The company is prioritizing patient safety and is in dialogue with the FDA regarding illegal compounding practices, but specifics on litigation were not disclosed [68] Question: What is the outlook for growth in China? - Management clarified that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth potential [75] Question: What changes in R&D focus can be expected? - The company will focus more on diabetes and obesity, reallocating resources to enhance growth in these core areas [82] Question: How is the company positioned for the launch of oral semaglutide? - The company is well-positioned for the launch of oral semaglutide for obesity next year, with no supply restrictions anticipated [103] Question: What are the pricing strategies for Wegovy and Ozempic? - Management is focused on volume growth but is also considering pricing strategies for the second half of the year [116]

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [7][44] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [44] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [48] Business Line Data and Key Metrics Changes - U.S. Operations grew by 17%, while international operations grew by 19% in total sales [12] - GLP-1 diabetes sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - Sales in international operations grew by 19%, with GLP-1 diabetes sales increasing by 10% [23] - Obesity care sales in international operations grew by 125%, with Wegovy sales alone reaching DKK 12.2 billion, growing at 335% [24] - The company remains the market leader in international operations with a 71% market share in GLP-1 products [25] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [31] - A focus on innovation and addressing diverse patient segments through a broad portfolio of treatments is emphasized [31] - The company plans to continue rolling out Wegovy in more countries and invest in commercial execution [26][31] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [7][51] - The company is confident in its ability to treat more people living with chronic diseases despite the adjustments in expectations [56] - The management highlighted the importance of operational efficiency and commercial execution moving forward [60] Other Important Information - The company announced an interim dividend of DKK 3.75 per share, a 7% increase compared to August 2024 [49] - Capital expenditure for 2025 is expected to be around DKK 65 billion, reflecting expansion of the global supply chain [54] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the CVS formulary conversion and sees it aligning with expectations, but specific numbers on lives affected were not disclosed [67][68] Question: Has Novo initiated any litigation regarding compounding practices? - Management confirmed that protecting patient safety is a priority and that legal actions are being considered, with ongoing dialogue with the FDA [68][69] Question: What is the outlook for growth in China? - Management stated that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth due to unmet needs [75][78] Question: What changes in R&D focus can be expected? - Management indicated a continued focus on diabetes and obesity, emphasizing execution and reallocating resources to areas of growth [81][83] Question: What is the rationale behind discontinuing development of Sulfiram for NASH? - The decision was based on a lack of differentiation from semaglutide in trials, which demonstrated strong efficacy [112][113]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 6, 2025 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé DK-2880 Bagsværd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F x Form 40-F o Indicate by check ma ...